World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
139
Citations
109864
World Ranking
1719
National Ranking
986

Overview

Clifford A. Hudis is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics, and Radiology, Nuclear Medicine and Imaging.

The scientist's publication record includes significant research in breast cancer treatment and related topics. Their work covers a range of subjects such as Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Estrogen and related hormone effects, Cancer Risks and Factors, and Cancer survivorship and care.

Notable recent papers authored or co-authored by Clifford A. Hudis include:

  • "Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors," 2020, Nature Cancer
  • "Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial," 2023, The Lancet Oncology
  • "Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer," 2020, Journal of Clinical Oncology
  • "Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy," 2020, JNCI Journal of the National Cancer Institute
  • "ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106," 2020, Journal of Clinical Oncology

Frequent co-authors in their collaborative work include:

  • Eric P. Winer
  • Lisa A. Carey
  • Ann H. Partridge
  • Donald A. Berry
  • Constance Cirrincione

Hudis' publications have appeared in several venues, with substantial contributions to:

  • UNC Libraries
  • Journal of Clinical Oncology
  • Cancer Prevention Research
  • Clinical Cancer Research
  • Cancer Research

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Trastuzumab — Mechanism of Action and Use in Clinical Practice

    Clifford A. Hudis

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

    Ethan Basch;Allison M. Deal;Mark G. Kris;Howard I. Scher

  • Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience

    Andrew Seidman;Clifford Hudis;Mary Kathryn Pierri;Steven Shak

  • Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

    J. Baselga;Debasish Tripathy;J. Mendelsohn;S. Baughman

  • Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

    Ethan Martin Basch;Allison M. Deal;Amylou C. Dueck;Howard I. Scher

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

    Noah D. Kauff;Jaya M. Satagopan;Mark E. Robson;Lauren Scheuer

  • American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff

  • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

    Weiyi Toy;Yang Shen;Helen Won;Bradley Green

  • Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

    Kevin S. Hughes;Lauren A. Schnaper;Jennifer R. Bellon;Constance T. Cirrincione

  • Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer

    Kevin S. Hughes;Lauren A. Schnaper;Donald Berry;Constance Cirrincione

  • Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*

    Abram Recht;Stephen B. Edge;Lawrence J. Solin;David S. Robinson

  • American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

    Harold J. Burstein;Ann Alexis Prestrud;Jerome Seidenfeld;Holly Anderson

  • Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

    William M. Sikov;Donald A. Berry;Charles M. Perou;Baljit Singh

  • Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study

    Rowan T. Chlebowski;George L. Blackburn;Cynthia A. Thomson;Daniel W. Nixon

  • Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

    Donald A. Berry;Constance Cirrincione;I. Craig Henderson;Marc L. Citron

Frequent Co-Authors

Larry Norton
Larry Norton Memorial Sloan Kettering Cancer Center
Eric P. Winer
Eric P. Winer Yale University
Andrew J. Dannenberg
Andrew J. Dannenberg Cornell University
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill
Harold J. Burstein
Harold J. Burstein Harvard University
Monica Morrow
Monica Morrow Memorial Sloan Kettering Cancer Center
Edi Brogi
Edi Brogi Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean attending a traditional MD program. Numerous asn to fnp bridge programs offer registered nurses a flexible route to becoming Family Nurse Practitioners—often entirely online.

For those interested in holistic health and preventive care, online nutrition degrees are a popular choice. These programs can open doors to careers in dietetics, wellness coaching, research, and public health.

If healthcare leadership interests you, many students choose cahme-accredited online mha programs. These degrees prepare graduates for managerial and executive roles in hospitals, clinics, and other healthcare organizations.

Finally, nurses looking to advance quickly without extra onsite clinicals are increasingly opting for rn to bsn programs. These programs enhance clinical knowledge and leadership skills—all online—making career advancement more accessible.

Exploring these online pathways lets students tailor their health careers to personal interests and schedules, making a rewarding future in medicine more attainable than ever.

Best Scientists Citing Clifford A. Hudis

Trending Scientists

Recently Published Articles